{"id":"NCT04169373","sponsor":"AbbVie","briefTitle":"A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis","officialTitle":"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects With Axial Spondyloarthritis Followed by a Remission-Withdrawal Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-26","primaryCompletion":"2021-09-02","completion":"2025-02-21","firstPosted":"2019-11-19","resultsPosted":"2022-09-21","lastUpdate":"2025-03-17"},"enrollment":734,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Spondyloarthritis"],"interventions":[{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","RINVOQ"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Study 1: Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Study 1: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Study 2: Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Study 2: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.\n\nThe main objectives of this protocol are:\n\n* To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2).\n* To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2).\n* To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2).\n* To evaluate the maintenance of disease control after withdrawal of upadacitinib.","primaryOutcome":{"measure":"Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14","timeFrame":"Baseline and Week 14","effectByArm":[{"arm":"Study 1: Placebo","deltaMin":18.2,"sd":null},{"arm":"Study 1: Upadacitinib 15 mg","deltaMin":44.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":212,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","France","Germany","Hungary","Israel","Japan","Mexico","New Zealand","Poland","Russia","Slovakia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40875187","40037923","39905436","39533349","38683479","37982966","37191738","36820984","35908570","35788492"],"seeAlso":["http://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":209},"commonTop":["COVID-19","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","HEADACHE"]}}